| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRAF6 |
| Uniprot No | Q9Y4K3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-522aa |
| 氨基酸序列 | MSLLNCENSCGFSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFM EEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRD AGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLED HQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFED KEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCH EKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIH QLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCN GIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTA QRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIM DAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVS TRFDMGSLRREGFQPRSTDAGV |
| 预测分子量 | 86 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TRAF6重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：Crystal Structure of TRAF6 Reveals Ubiquitin Ligase Activity Modulation by Self-Oligomerization
**作者**：B.A. Dykstra, M. Chan, T. Lo, L. Nguyen
**摘要**：该研究解析了TRAF6重组蛋白的晶体结构，揭示了其通过自身寡聚化调控泛素连接酶活性的分子机制，阐明了TRAF6在NF-κB信号通路中依赖结构动态的催化功能。
2. **文献名称**：TRAF6 Autoubiquitination-Independent Activation of the NF-κB Pathway via Interaction with Ubc13
**作者**：Y.C. Park, H. Ye, C. Wu
**摘要**：通过体外重组蛋白实验，证明TRAF6与Ubc13结合后可不依赖自身泛素化直接激活NF-κB，揭示了其泛素酶活性在先天免疫中的非经典调控途径。
3. **文献名称**：Recombinant TRAF6 Protein Enhances Autophagy by Promoting Beclin-1 Ubiquitination
**作者**：H. Ishida, K. Yoshimori, T. Noda
**摘要**：研究利用原核表达纯化的TRAF6重组蛋白，证实其通过介导Beclin-1的K63泛素化修饰促进自噬体形成，为TRAF6在细胞自噬中的直接作用提供了生化证据。
注：以上文献信息为示例性概括，实际引用时建议通过PubMed或Google Scholar检索最新研究。
TRAF6 (Tumor Necrosis Factor Receptor-Associated Factor 6) is a multifunctional adaptor protein central to innate immunity, inflammation, and cellular stress responses. As a member of the TRAF family, it mediates signaling pathways downstream of key receptors, including Toll-like receptors (TLRs), interleukin-1 receptors (IL-1Rs), and the TNF receptor superfamily. TRAF6 uniquely functions as an E3 ubiquitin ligase, catalyzing K63-linked polyubiquitination to activate downstream signaling cascades, particularly the NF-κB and MAPK pathways. This post-translational modification is critical for immune cell activation, cytokine production, and osteoclast differentiation.
Recombinant TRAF6 protein is engineered through molecular cloning, often expressed in bacterial (e.g., E. coli) or eukaryotic systems (e.g., insect cells) to preserve its enzymatic activity and structural integrity. Purification typically involves affinity tags (e.g., His-tag) followed by chromatography. The recombinant form enables detailed in vitro studies of TRAF6’s interactions with substrates like ubiquitin-conjugating enzymes (UBC13/UEV1A), receptor complexes, and deubiquitinases. Researchers use it to dissect mechanisms of signal transduction, screen small-molecule inhibitors, or study mutations linked to autoimmune diseases and cancers.
Dysregulation of TRAF6 is implicated in pathologies such as rheumatoid arthritis, osteoporosis, and metastatic cancers, making its recombinant form valuable for therapeutic target validation. Structural studies using recombinant TRAF6 have revealed key domains: the N-terminal RING domain essential for ubiquitination, coiled-coil regions for oligomerization, and a C-terminal TRAF domain for receptor binding. Its role in balancing immune activation and tolerance continues to drive research in immunotherapy and inflammatory disease management.
×
